{
  "docId": "019de072-f0cb-7745-907c-f9e6b87d2817",
  "docSlug": "e5afd111c5ca3d26ccce5d5b91b81d60",
  "documentTitle": "BioNTech | Investor Day Presentation Deck | 156 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 69,
  "pageCount": 120,
  "prevPage": 68,
  "nextPage": 70,
  "slideType": "comparison_table",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "The table highlights the seroresponse difference and non-inferiority status for participants without prior infection.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-f0cb-7745-907c-f9e6b87d2817/69",
  "deckHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817",
  "deckJsonHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817.json",
  "deckAnchorHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817#slide-69",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "Non-inferiority criterion: the lower bound of 95% confidence interval for interval for the percentage difference is >-5",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d758f03-d791-497b-bacc-cf21c5370e78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Multiple hypotheses are to be evaluated in sequential order for alpha control. Declaration of OMI 30 µg noninferiority pending outcome of additional hypotheses. Note: Omicron BA.1 NT50 measured using validated 384-well assay. Internal data.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "336d6fe7-f202-4153-9b3c-9e0dd42bdd17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "subtitle",
      "text": "Participants WITHOUT evidence of infection up to 1 month after the study vaccination",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6f63898-430e-4e0b-95d4-127b01777e4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "table",
      "text": "Comparison of seroresponse rates and non-inferiority metrics across vaccine groups.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eba41255-2b05-4749-a233-3b801628b2ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Variant-adapted vaccines | Omicron BA.1 seroresponse rate exceeds noninferiority criterion for Omicron-containing vaccines (>55y participants)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45cd850e-e219-41d1-a371-029d200567d1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 70,
      "from": 60,
      "beatId": "ad024950-7f4b-4056-b7c8-680591fc503c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Opportunity",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The presentation highlights the market opportunity in infectious diseases and oncology",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}